Drugs / rhG-CSF
rhG-CSF
also known as
recombinant human granulocyte colony-stimulating factor · filgrastim · G-CSF · Topneuter
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01441427 | Jan 2010 → Apr 2011 | necrotizing enterocolitis | Ain Shams University | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04466137 | Oct 2020 → Jun 2021 | neoplasm | Xiamen Amoytop Biotech Co., Ltd. | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT04083079 | Aug 2019 → Aug 2021 | non-Hodgkin lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01479114 | Apr 2009 → May 2010 | neonatal sepsis | Ain Shams University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05531279 | Jun 2022 → Jun 2025 | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| — | NCT04497701 | Aug 2020 → Aug 2021 | leukemia, lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 2 | NCT04542356 Background | Aug 2018 → Jan 2021 | cervical cancer | Chongqing University Cancer Hospital | Completed | Met primary |
| Phase 2 | NCT02119715 Comparator | Feb 2011 → Aug 2012 | breast cancer, neutropenia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01560195 Comparator | Apr 2012 → Jan 2013 | neutropenia, non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01611051 Comparator | Mar 2012 → Jan 2013 | breast cancer, neutropenia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT06026995 Comparator | Mar 2022 → Jan 2024 | lymphoma | Chongqing University Cancer Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03206684 Comparator | Aug 2017 → Jul 2018 | cervical cancer | Air Force Military Medical University, China | Unknown | No outcome recorded |
| Phase 4 | NCT02996617 Comparator | Nov 2016 → Nov 2018 | non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02905942 Comparator | Dec 2015 → Dec 2018 | lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT02805153 Comparator | Apr 2013 → Feb 2016 | breast cancer | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| — | NCT05834751 Comparator | May 2023 → May 2025 | lymphoma | Ou Bai, MD/PHD | Unknown | No outcome recorded |
| — | NCT05156554 Comparator | Dec 2021 → Dec 2022 | lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT04500886 Comparator | Aug 2020 → Aug 2021 | hemophagocytic syndrome | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-03-06 | Novartis Pharmaceuticals | FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz novartis.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhG-CSF | “Patients with NSCLC who received 1-4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2 mg, 33 µg/kg or control drug (rhG-CSF...” PMID 40098083 ↗ Mar 202517“enteral recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human erythropoietin (rhEPO) in preventing feeding intolerance” PMID 25155966 ↗ Aug 2014 |
| Known as | filgrastim | “patients received daily subcutaneous injections of rhG-CSF(filgrastim) 5 ug/ kg/day.” NCT02805153 ↗ |
| Known as | G-CSF | “This study compared the efficacy of PEG-rhG-CSF with that of recombinant human granulocyte colony-stimulating factor (G-CSF) in preventing neutropenia after chemotherapy for lymphoma.” PMID 41510127 ↗ Dec 2025 |
| Known as | recombinant human granulocyte colony-stimulating factor | “This study compared the efficacy of PEG-rhG-CSF with that of recombinant human granulocyte colony-stimulating factor (G-CSF) in preventing neutropenia after chemotherapy for lymphoma.” PMID 41510127 ↗ Dec 20251“Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is an effective drug for the treatment of chemotherapy-induced neutropenia.” NCT02996617 ↗ |
| Known as | Topneuter | “Patients with NSCLC who received 1-4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2 mg, 33 µg/kg or control drug (rhG-CSF...” PMID 40098083 ↗ Mar 2025 |
| Modality | Protein / enzyme biologic | “recombinant human granulocyte colony-stimulating factor (rhG-CSF)” PMID 25155966 ↗ Aug 2014 |
| Route | Other | “administered once daily by an orogastric tube” NCT01441427 ↗ |